Thus, our results support conducting preclinical studies of semaglutide (and other GLP1R agonist) on THC and randomized clinical trials to evaluate the therapeutic benefits of semaglutide in CUD in individuals with obesity or T2D as well as in patients with CUD who don’t have these co-morbid conditions. Here, GLP1R is linked to Obesity.